Ticagrelor Tablet
Product Images NDC 60687-928

Product Visual Gallery

This gallery contains 21 technical images submitted to the FDA as part of the official labeling for Ticagrelor (NDC 60687-928). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

90 mg Ticagrelor Tablet Blister.jpg (90 mg Ticagrelor Tablet Blister)

This text describes a medication called Ticagrelor in the form of tablets with a strength of 90 mg. The text seems to be a combination of errors and part of the information is repeated. It is used for preventing blood clots and is often prescribed for patients with certain medical conditions.*

FDA Label Image

90 mg Ticagrelor Tablets Carton.jpg (90 mg Ticagrelor Tablets Carton)

This text contains information about Ticagrelor tablets, with each tablet containing Ticagrelor 90mg. The usual adult dosage information is provided, along with storage instructions between 20°C to 25°C. The NDC number for this product is 60687-928-57. The medication is distributed by American Health Packaging in Columbus, Ohio. This is a prescription-only medication that comes in a package containing 60 tablets (6 x 10). It is important not to use damaged or broken tablets.*

FDA Label Image

Figure1.jpg (Figure1)

This is a comparison between two drugs, Ticagrelor and Clopidogrel, in a study with a total of 9235 and 9186 patients, respectively. The study shows that 3.9% of patients on Ticagrelor experienced events compared to 3.3% on Clopidogrel. The Kaplan-Meier percentage at 12 months was 45% for Ticagrelor and 38% for Clopidogrel. The chart displays the number of patients at risk over time from the first dose of the study drugs.*

FDA Label Image

Figure10.jpg (Figure10)

This text contains data related to a clinical study comparing two treatments (Tigomg and Clopidogrel) for patients with events. It includes the number of patients, Kaplan-Meier survival percentages at 12 months, hazard ratio, p-value, and the number of days from randomization with corresponding counts at different time points. The results indicate a statistically significant difference between the two treatments in terms of outcome.*

FDA Label Image

Figure11.jpg (Figure11)

This is a clinical trial summary detailing various characteristics of the study participants and the treatment outcomes observed. The data includes information on geographic region, treatment approaches, patient demographics (age, sex, race), medical history (diabetes, prior TIA/Stroke), and the use of medications (Glycoprotein lib/llla Inhibitor). The treatment effect is evaluated based on the primary endpoint, with comparisons between Ticagrelor and Clopidogrel. The statistical analysis includes odds ratios (AR) with corresponding 95% confidence intervals, indicating the efficacy of each treatment option. The text presents a detailed breakdown of the data by subgroups, providing insights into the impact of different factors on treatment outcomes.*

FDA Label Image

Figure12.jpg (Figure12)

This table provides data on the distribution of patients in different regions based on different treatments and outcomes. The data includes the number of patients in each group, as well as the corresponding risk ratios with 95% confidence intervals. The regions are divided into US and non-US categories, and treatments compared are Ticagrelor and Clopidogrel. The table suggests a comparison between the effectiveness of Ticagrelor and Clopidogrel in different regions based on the given data.*

FDA Label Image

Figure13.jpg (Figure13)

This text appears to be a comparison of the effects of Ti90mg, Ti60mg, and Placebo on patients over a period of 36 months. It includes data on the number of patients with events, Kaplan-Meier percentage at 36 months, hazard ratio (HR) with confidence intervals, p-values, and the number of patients at risk over time. The results indicate that Ti90mg and Ti60mg show a reduction in events compared to Placebo, with Ti60mg showing a slightly higher percentage at 36 months. The data suggests a potential benefit of Ti90mg and Ti60mg in reducing events over the 36-month period.*

FDA Label Image

Figure14.jpg (Figure14)

This is a data table showing various characteristics and efficacy outcomes of a treatment in different subgroups. It includes information on treatment effect, patient demographics, medical history, and response to medication. The table also includes hazard ratios (HR) with 95% confidence intervals for different endpoints, providing insights into the effectiveness of the treatment in different scenarios. The data seems to be related to a clinical trial evaluating the impact of a medication, possibly Ticagrelor, on different patient subgroups.*

FDA Label Image

Figure15.jpg (Figure15)

FDA Label Image

Figure16.jpg (Figure16)

This data pertains to a clinical study evaluating the effects of Ticagrelor compared to Placebo in patients with certain characteristics such as age, sex, race, body mass index, and medical history. The information includes the percentage distribution of patients based on different parameters like age, sex, race, aspirin dose, HbA1c levels, eGFR at baseline, insulin use, and history of various cardiovascular conditions like angina, PCI with stent, and CABG. The study also provides the number of patients who experienced an event per year (%) in each group (Ticagrelor vs. Placebo) and the Hazard Ratio (with 95% Confidence Interval) for each subgroup. This data could be used to analyze the effectiveness of Ticagrelor compared to Placebo in different patient subgroups.*

FDA Label Image

Figure17.jpg (Figure17)

This is a data table showing the comparison between Ticagrelor 90mg and Placebo in terms of events, number at risk, days from randomization, and cumulative percentage. Ticagrelor had 303 events out of 5523 cases (5.4%), while Placebo had 362 events out of 5493 cases (6.5%). The table displays the cumulative percentage over time for each group.*

FDA Label Image

Figure18.jpg (Figure18)

The text provides data on the evaluation of ticagrelor versus placebo in different subgroups based on characteristics such as age, sex, race, weight, BMI, geographic region, diagnosis of index event, time from index event, diabetes mellitus, hypertension, prior stroke or TIA, ischaemic heart disease, ASA and statin treatment, smoking status, and others, showing hazard ratios with confidence intervals. The analysis compares the efficacy of ticagrelor and placebo within these subgroups.*

FDA Label Image

Figure2.jpg (Figure2)

This text appears to be a graph showing the percentage of patients who had an event following a CABG procedure over time. The x-axis represents the days after the procedure, and the y-axis represents the percentage of patients experiencing an event. It seems like there are different groups or categories of patients shown in the graph.*

FDA Label Image

Figure3.jpg (Figure3)

This text shows data on the cumulative percentage of events for Ticagrelor and Placebo over time. The number of events and participants at risk for each treatment group are provided for different months from randomization. These numbers give insights into the effectiveness and safety of Ticagrelor compared to placebo for the given conditions. The data can be used for further analysis and to draw conclusions about the outcomes of interest.*

FDA Label Image

Figure4.jpg (Figure4)

Not available.*

FDA Label Image

Figure5.jpg (Figure5)

FDA Label Image

Figure6.jpg (Figure6)

FDA Label Image

Figure7.jpg (Figure7)

FDA Label Image

Figure8.jpg (Figure8)

The text provides information on interacting drugs with Ticagrelor and their effects on specific enzymes. It lists strong, moderate, and potent CYP3A4 inhibitors, as well as potent CYP3A4 inducers and P-gP and CYP3A inhibitors. Recommendations for dose adjustments and avoiding concomitant use are included in the text.*

FDA Label Image

Figure9.jpg (Figure9)

FDA Label Image

Structure.jpg (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.